Gemtuzumab ozogamicin for untreated acute myeloid leukaemia

  • Technology appraisal guidance
  • TA545
  • Published: 
Following receipt of further analyses, the committee will continue its decision making as a short agenda item at the meeting on Wednesday 22 August 2018.